Launching in 2027, we are an early-stage venture firm investing at the convergence of AI and biotechnology, backing bold, technical founders building the platforms that will define the next era of medicine. We focus on proprietary data engines that own their feedback cycle and biological platforms that generalize across therapeutic areas.